Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $88 from $72 and keeps an Overweight rating on the shares following the Q3 report.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $102 from $69 at Citizens JMP
- Protagonist Therapeutics price target raised to $91 from $74 at Clear Street
- Protagonist Therapeutics Advances Pipeline Amid Financial Loss
- Promising Developments and Strategic Progress at Protagonist Therapeutics Drive Buy Rating
- Protagonist Therapeutics reports Q3 EPS (62c), consensus (64c)